Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Epigral Ltd
| Q3 FY26 Earnings Conference Call
Summary : Epigral faced Q3 margin pressure from costs and lower realizations but anticipates strong recovery and growth from Q4 onwards, driven by capacity expansions and improving market demand.
Management Perspective positive : "We expect this positive momentum to persist in future quarters.""As utilization improves, overall performance should strengthen further.""Outlook indicates improved performance in coming quarters, supported by strengthening demand.""We are advancing with clarity on milestone, capital efficiency and disciplined execution to deliver sustainable growth.""Compared to last 6 months, everything will only improve. It is going to be on the positive side."
Concall Report Analysis & Insights
Business Overview
- Q3 FY26 revenue grew marginally by 2% sequentially, with flat volumes.
- Derivatives and specialty business contributed 52% of Q3 revenue, up from 50%.
- EBITDA margins contracted to 17% in Q3 due to lower realizations, rising raw material costs, and high inventory.
- 9-month FY26 EBITDA margins sustained at 22%, with 76% plant utilization.
- Overall plant utilization was 78% in Q3 FY26, similar to the prior quarter.
Future Growth Prospects
- Expect sustained growth and improved performance from mid-November volume pickup.
- CPVC, epichlorohydrin, and wind solar hybrid power capex projects are on schedule.
- Chlorotoluene value chain commissioned in March 2025, driving strong FY27 growth.
- New capex plans for integrated complex and value chain expansion expected for FY29 growth.
- Targeting 70% revenue from derivatives and specialty business through diversification.
Management Insights
- Chemical market shows mixed performance, but outlook indicates improved performance ahead.
- Volume pickup since mid-November is expected to lead to sustained growth.
- Capex projects are on schedule, supporting diversification and targeting 70% specialty revenue.
- Chlorotoluene value chain commissioned in March '25, contributing significantly from FY27.
- Team is focused on scalable, profitable growth, strengthening integration, and capital efficiency.
Signs of Skepticism
- Management is vague on exact utilization percentages for new products like chlorotoluene.
- Specific timelines for new chemistry announcements are not yet public.
- Downplays potential long-term CPVC pricing pressure from large new competitor capacities.
- Difficult to predict exact commissioning dates and optimization levels for new plants.
Risk Factors
- Chemical market faces mixed performance, with some segments showing slower recovery.
- Prolonged monsoon, festive disruptions, and plant maintenance impacted Q3 volumes.
- Lower realizations, rising raw material costs, and high inventory pressured Q3 EBITDA margins.
- Potential pricing pressure in CPVC from new large capacities by Reliance and Adani.
- Initial 6-12 months of lower utilization expected for new plants post-commissioning.
Good To Know
- Net debt to EBITDA stood at 1x as on 31st December '25, up from 0.8x last year.
- INR337 crores capex spent during the year, with plans moving as per schedule.
- A pilot plant is being built for internal testing and quality improvement across products.
- Labor Code implementation expense was booked in Q3, but the amount was very small.
- Chlorine integration is currently around 70-75%, with negative chlorine pricing around INR7,000.
Key Drivers
- New capacity commissioning on schedule.
- Chlorotoluene plant contribution from FY27.
- Demand recovery post-monsoon.
- Rising PVC and ECH prices.
Key Analyst Discussions
Competitive Environment
- Reliance and Adani are building large PVC capacities, but CPVC capacity announcements are smaller.
- New large caustic soda capacities by Adani and Reliance may lead to lower caustic and higher chlorine prices.
- European epichlorohydrin manufacturers closing plants may benefit Indian producers in coming years.
- Imports from Bangladesh continue to impact hydrogen peroxide realizations.
- China withdrawing product rebates and currency appreciation may positively impact local manufacturing.
Market Trends & Consumer Behavior
- PVC prices have bottomed out and are now improving, expected to boost CPVC pricing.
- Overall chemical industry pressure seen in the last 9 months is expected to improve.
- Demand for CPVC is growing, driven by real estate sector growth, expected to reach 5 lakh tonnes by FY29-30.
- Glycerin prices are rising globally, impacting ECH prices, as most new ECH plants are glycerin-based.
- Q3 and Q4 are typically higher consumption periods for the company's products.
Financial Highlights
- Q3 EBITDA dropped 22% due to lower realizations and higher raw material/inventory costs.
- ECU for Q3 was INR29,000-INR30,000, marginally down from last quarter.
- CPVC realization is INR95-INR100 per kg, ECH realization is INR165-INR170 per kg.
- Expect Q4 margins to uptick, reaching 21-23% range, driven by PVC/CPVC price increases.
- Chlorotoluene is expected to contribute sizably to profit from FY27 onwards.
Product Composition
- Derivatives and specialty business increased its revenue contribution to 52% in Q3.
- Chlorotoluene volumes are increasing month-on-month and quarter-on-quarter.
- CPVC was significantly impacted by softer realizations in Q3.
- ECH value is increasing due to rising glycerin prices, as 65% of global demand is glycerin-based.
Strategic Considerations
- Doubling CPVC and epichlorohydrin capacity, expecting demand absorption within 1-2 years.
- No current plans for forward integration into epoxy from ECH production.
- Not planning to enter CPVC pipe manufacturing, pilot plant is for internal testing.
- Finalizing plans for new chemistry, expecting an announcement in a couple of months.
- Management anticipates demand growth will absorb new capacities in CPVC and ECH over time.